Bortezomib, a proteasome inhibitor, in cancer therapy: From concept to clinic

Drugs of the Future

Volumn 27, Issue 11, 2002, Pages 1079-1092

  Albanell, Joan ^a   Adams, Julian ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BORTEZOMIB; CARBOPLATIN; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN E; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; I KAPPA B; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PROTEASOME; PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN INK; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN TOPO 1; PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR E2F; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; GENE EXPRESSION; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; REVIEW; SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

EID: 0036879427     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.11.697067     Document Type: Review

References (105)

1. Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., Goldberg, A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78: 761-71.
2. Zwickl, P., Voges, D., Baumeister, W. The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc London B Biol Sci 1999, 354: 1501-11.
3. Ciechanover, A. The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 1998, 17: 7151-60.
4. MacLaren, A.P., Chapman, R.S., Wyllie, A.H., Watson, C.J. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001, 8: 210-8.
5. Wilkinson, K.D. Ubiquitin-dependent signaling: The role of ubiquitination in the response of cells to their environment. J Nutr 1999, 129: 1933-6.
6. Pickart, C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70: 503-33.
7. Thrower, J.S., Hoffman, L., Rechsteiner, M., Pickart, C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000, 19: 94-102.
8. DeMartino, G.N., Slaughter, C.A. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999, 274: 22123-6.
9. Nussbaum, A.K., Dick, T.P., Keilholz, W. et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998, 95: 12504-9.
10. Tan, C., Waldmann, T.A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002, 62: 1083-6.
11. Adams, J., Palombella, V.J., Elliott, P.J. Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 2000, 18: 109-21.
12. Shah, S.A., Potter, M.W., McDade, T.P., Ricciardi, R., Perugini, R.A., Elliott, P.J., Adams, J., Callery, M.P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001, 82: 110-22.
13. Wu, Y., Luo, H., Kanaan, N., Wu, J. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000, 76: 596-604.
14. Lopes, U.G., Erhardt, P., Yao, R., Cooper, G.M. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997, 272: 12893-6.
15. Maki, C.G., Huibregtse, J.M., Howley, P.M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996, 56: 2649-54.
16. Naujokat, C., Sezer, O., Zinke, H., Leclere, A., Hauptmann, S., Possinger, K. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000, 65: 221-36.
17. An, W.G., Hwang, S.G., Trepel, J.B., Blagosklonny, M.V. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14: 1276-83.
18. Jeremias, I., Kupatt, C., Baumann, B., Herr, I., Wirth, T., Debatin, K.M. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998, 91: 4624-31.
19. Delic, J., Masdehors, P., Omura, S., Cosset, J.M., Dumont, J., Binet, J.L., Magdelenat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF- α-initiated apoptosis. Br J Cancer 1998, 77: 1103-7.
20. Kudo, Y., Takata, T., Ogawa, I., Kaneda, T., Sato, S., Takekoshi, T., Zhao, M., Miyauchi, M., Nikai, H. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000, 6: 916-23.
21. Ma, M.H., Parker, K.M., Manyak, S. et al. Proteasome inhibitor PS-341 markedly enhanced sensitivity of multiple myeloma cells to chemotherapeutic agents and overcome resistance through inhibition of the NF-κB pathway. Blood 2001, 98(11, Part 1): Abst 1978.
22. Masdehors, P., Omura, S., Merle-Beral, H., Mentz, F., Cosset, J.M., Dumont, J., Magdelenat, H., Delic, J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999, 105: 752-7.
23. Soligo, D., Servida, F., Delia, D., Fontanella, E., Lamorte, G., Caneva, L., Fumiatti, R., Lambertenghi Deliliers, G. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001, 113: 126-35.
24. Orlowski, R.Z., Eswara, J.R., Lafond-Walker, A., Grever, M.R., Orlowski, M., Dang, C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998, 58: 4342-8.
25. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S., Elliott, P.J. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999, 59: 2615-22.
26. Drexler, H.C. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997, 94: 855-60.
27. Drexler, H.C., Risau, W., Konerding, M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000, 14: 65-77.
28. Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N, Ichihara, A. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991, 51: 6677-85.
29. Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S., Ichihara, A. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990, 87: 7071-5.
30. Ren, S., Smith, M.J., Louro, I.D. et al. The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene 2000, 19: 1419-27.
31. Mulligan, G., D'Cruz, C., Palermo, A., Meyer, R., Deeds, J., Bryant, B., Tucker-Kellogg, G., Kim, S., Lillie, J., Brown, J. Elevated expression of the proteasome in cancer. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1764.
32. Oikawa, T., Sasaki, T., Nakamura, M., Shimamura, M., Tanahashi, N., Omura, S., Tanaka, K. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998, 246: 243-8.
33. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L., Stein, R.L. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids, Bioorg Med Chem Lett 1998, 8: 333-8.
34. Kisselev, A.F., Goldberg, A.L. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001, 8: 739-58.
35. Bogyo, M., McMaster, J.S., Gaczynska, M., Tortorella, D., Goldberg, A.L., Ploegh, H. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HsIV by a new class of inhibitors. Proc Natl Acad Sci USA 1997, 94: 6629-34.
36. An, B., Goldfarb, R.H., Siman, R., Dou, Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5: 1062-75.
37. Dick, L.R., Cruikshank, A.A., Destree, A.T. et al. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 1997, 272: 182-8.
38. Groll, M., Koguchi, Y., Huber, R., Kohno, J. Crystal structure of the 20S proteasome:TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol 2001, 311: 543-8.
39. Meng, L., Mohan, R., Kwok, B.H., Elofsson, M., Sin, N., Crews, C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999, 96: 10403-8.
40. Meng, L., Kwok, B.H., Sin, N., Crews, C.M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999, 59: 2798-801.
41. Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J., Schreiber, S.L, Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268: 726-31.
42. Kozlowski, L., Stoklosa, T., Omura, S., Wojcik, C., Wojtukiewicz, M.Z., Worowski, K., Ostrowska, H. Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol 2001, 22: 211-5.
43. Frankel, A., Man, S., Elliott, P., Adams, J., Kerbel, R.S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000, 6: 3719-28.
44. Rousseau, D., Cannella, D., Boulaire, J., Fitzgerald, P., Fotedar, A., Fotedar, R. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene 1999, 18: 4313-25.
45. Teicher, B.A., Ara, G., Herbst, R., Palombella, V.J., Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5: 2638-45.
46. Sunwoo, J.B., Chen, Z., Dong, G., Yeh, N., Crowl Bancroft, C., Sausville, E., Adams, J., Elliott, P., Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7: 1419-28.
47. Cusack, J.C. Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J., Baldwin, A.S. Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition. Cancer Res 2001, 61: 3535-40.
48. Gumerlock, P.H., Kawaguchi, T., Moisan, L.P., Lau, A.H., Mack, P.C., Lara, P.N. Jr., Gandara, D.R. Mechanisms of enhanced cytotoxicity from docetaxel/PS-341 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1214.
49. 2/M phase arrest and apoptosis in human nonsmall cell lung cancer cells. Proc Am Assoc Cancer Res 2002, 43: Abst 3299.
50. Lloyd, R.V., Erickson, L.A., Jin, L., Kulig, E., Qian, X., Cheville, J.C., Scheithauer, B.W. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154: 313-23.
51. , St Croix, B., Florenes, V.A., Rak, J.W., Flanagan, M., Bhattacharya, N., Slingerland, J.M., Kerbel, R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996, 2: 1204-10.
52. Hideshima, T., Richardson, R, Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J., Anderson, K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61: 3071-6.
53. Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., Ben Neriah, Y. Stimulation-dependent I kappa B α phosphorylation marks the NF-κK inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1995, 92: 10599-603.
54. Chen, Z., Hagler, J., Palombella, V.J., Melandri, F., Scherer, D., Ballard, D., Maniatis, T. Signal-induced site-specific phosphorylation targets I κ B α to the ubiquitin-proteasome pathway. Genes Dev 1995, 9: 1586-97.
55. Lin, Y.C., Brown, K., Siebenlist, U. Activation of NF-κB requires proteolysis of the inhibitor I α B-α: Signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-κB. Proc Natl Acad Sci USA 1995, 92: 552-6.
56. Chen, C., Edelstein, L.C., Gelinas, C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol 2000, 20: 2687-95.
57. Rameshwar, P., Narayanan, R., Qian, J., Denny, T.N., Colon, C., Gascon, P. NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: An inflammatory response beyond the realm of homeostasis. J Immunol 2000, 165: 2271-7.
58. Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V., Baldwin, A.S. Jr. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281: 1680-3.
59. Wang, C.Y., Guttridge, D.C., Mayo, M.W., Baldwin, A.S. Jr. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19: 5923-9.
60. Zong, W.X., Edelstein, L.C., Chen, C., Bash, J., Gelinas, C. The prosurvival Bcl-2 homolog Bfl-/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 1999, 13: 382-7.
61. Patel, N.M., Nozaki, S., Shortle, N.H. et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000, 19: 4159-69.
62. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001, 107: 241-6.
63. Berenson, J.R., Ma, H.M., Vescio, R. The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Semin Oncol 2001, 28: 626-33.
64. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M., Jordan, C.T. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98: 2301-7.
65. Biswas, D.K., Cruz, A.P., Gansberger, E., Pardee, A.B. Epidermal growth factor-induced nuclear factor κ B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000, 97: 8542-7.
66. Biswas, D.K., Dai, S.C., Cruz, A., Weiser, B., Graner, E., Pardee, A.B. The nuclear factor kappa B (NF-κB). A potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 2001, 98: 10386-91.
67. Nakshatri, H., Bhat-Nakshatri, P., Martin, D.A., Goulet, R.J. Jr., Sledge, G.W. Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997, 17: 3629-39.
68. Sovak, M.A., Bellas, R.E., Kim, D.W., Zanieski, G.J., Rogers, A.E., Traish, A.M., Sonenshein, G.E. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100: 2952-60.
69. Garg, A., Aggarwal, B.B. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 2002 16: 1053-68.
70. Cusack, J.C., Liu, R., Baldwin, A.S. NF-κB and chemoresistance: Potentiation of cancer drugs via inhibition of NF-κB. Drug Resist Updates 1999, 2: 271-3.
71. Schenkein, D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002, 3: 49-55.
72. Fleming, J.A., Lightcap, E.S., Sadis, S., Thoroddsen, V., Bulawa, C.E., Blackman, R.K. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proc Natl Acad Sci USA 2002, 99: 1461-6.
73. Mulligan, G., D'Cruz, C., Kim, S., Palermo, A., Stec, J., Bryant, B., Tucker-Kellog, G., Brown, J. Coordinate regulation of proteasome genes in cancer. Proc Am Assoc Cancer Res 2002, 43: Abst 5373.
74. Nawrocki, S.T., McConkey, D. The proteasome inhibitor, PS-341, inhibits the growth of pancreatic cancer cells in vitro and in vivo. Proc Am Assoc Cancer Res 2002, 43: Abst 792.
75. Chen, Z., Malhotra, P.S., Gill, R., Yeh, N.T., Van Waes, C. Identification of sensitive and resistant head and neck squamous cell carcinoma lines to PS-341, a novel anticancer agent inhibiting proteasome dependent activation of NF-κB. Proc Am Assoc Cancer Res 2002, 43: Abst 789.
76. Bold, R.J., Virudachalam, S., McConkey, D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001, 100: 11-7.
77. Russo, S.M., Tepper, J.E., Baldwin, A.S. Jr., Liu, R., Adams, J., Elliott, P., Cusack, J.C. Jr. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001, 50: 183-93.
78. Thorton, J.D., Liu, R., Orlowski, M. et al. Doxorubicin-induced NF-κB activation in breast cancer is overcome by proteasome inhibition, resulting in enhanced tumoricidal response to treatment. Am Coll Surgeons Owen H Wagensteen Surgical Forum 2001, L11: 201-2.
79. Thomas, J.P., Arzoomanian, R., Alberti, D. et al. A phase 1 and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 368.
80. Williams, S.A., Papandreou, C., McConkey, D. Preclinical effects of proteasome inhibitor PS-341 in combination chemotherapy for prostate cancer Proc Am Soc Clin Oncol 2001, 20(Part 2): Abst 2427.
81. Pervan, M., Pajonk, F., Sun, J.R., Withers, H.R., McBride, W.H. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001, 24: 481-5.
82. Aghajanian, C., Soignet, S., Dizon, D.S., Pezzulli, S., Daud, A., Spriggs, D.R., Adams, J., Elliott, P., Pien, C. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 338.
83. Erlichman, C., Adjei, A.A., Thomas, J.P. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 337.
84. Hamilton, A.L., Eder, J.P., Pavlick, A.C. et al. PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 336.
85. Papandreou, C., Daliani, D., Millikan, R.E., et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 340.
86. Stinchombe, T.E., Mitchell, B.S., Depcik-Smith, N., Adams, J., Elliott, P., Shea, T.C., Orlowski, R.Z. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematological malignancies. Blood 2000, 96(11, Part 1): Abst 2219.
87. Lightcap, E.S., McCormack, T.A., Pien, C.S., Chau, V., Adams, J., Elliott, P.J. Proteasome inhibition measurements: Clinical application. Clin Chem 2000, 46: 673-83.
88. Nix, D., Pien, C., Newman, R., Madden, T., Felix, E., Adams, J. Elliott, P. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 339.
89. Adams, J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7: 9-16.
90. Adams, J. Proteasome inhibition: A novel approach to cancer therapy. Trends Mol Med 2002, 8: S49-54.
91. Available at http://clinicaltrials.gov/. (Accessed August 20, 2002). National Library of Medicine Clinical Trials gov [Web page].
92. Richardson, P.G., Barlogie, B., Berenson, J. et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 40.
93. Logothegis, C.J., Yang, H., Daliani, D. et al. Dose dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (Al PCa) treated with the proteasome inhibitor PS-341. Proc Am Soc Clin Oncol 2001 20(Part 1): Abst 740.
94. Shah, M.H., Martin, E., Ellison, C., Kraut, E., Kindler, H., Young, D., Kleiber, B., Wright, J. A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 111.
95. Adams J. The proteasome as a novel target for the treatment of breast cancer. Submitted.
96. Pink, M.M., Pien, C.S., Worland, P., Adams, J., Kauffman, M. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 2002, 43: Abst 787.
97. Das, K.C., White, C.W. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997, 272: 14914-20.
98. Wang, C.Y., Mayo, M.W., Baldwin, A.S. Jr. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996, 274: 784-7.
99. Wang, C.Y., Cusack, J.C. Jr., Liu, R., Baldwin, A.S. Jr. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999, 5: 412-7.
100. Ng, B., Kramer, E., Devitt, M.L., Elliott, P., Ceriani, R., Hamilton, A., Fumanski, P., Formenti, S., Liebes, L. Proteasome inhibitor PS-341, enhances in vitro radiosensitivity of human breast cancer cells treated with radiotherapy or radioimmunotherapy. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abst 758.
101. Sayers, T.J., Brooks, A., Seki, N., Murphy, W.J., Elliott, P. The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated apoptosis. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abst 319.
102. Mimnaugh, E.G., Neckers, L. Biological rationale for the combination of an Hsp90 antagonist with a proteasome inhibitor. AACR-NCI-EORTC Int Con Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abst 623.
103. Clark, J.W., Ryan, D., Dees, C. et al. Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 369.
104. Ryan, D.P., Eder, J.P., Winkelmann, J. et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 379.
105. Iqbal, S., Lenz, H.-J., Groshen, S. et al. Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 370.